Latest CARB-X Annual Report Shows $127.5M, 23 Awards Dolled Out for Solutions to Drug-Resistant Bacteria
Kevin Outterson is quoted.
October 23, 2020 Homeland Preparedness NewsCARB-X is Funding Polyphor to Develop a New Antibiotic to Treat Multidrug-Resistant Enterobacteriaceae Gram-Negative Bacterial Infections
This is Polyphor’s second innovative antibiotic program to be funded by CARB-X.
Bennet, Young Introduce Legislation to Fight Antimicrobial Resistance
Kevin Outterson is quoted.
CARB-X Funds Evotec to Develop a New Class of Broad-Spectrum Antibiotics to Treat Multidrug-Resistant Bacterial Infections
First pharmaceutical R&D company based in Germany in the CARB-X portfolio.
Racing the Clock to Stop Drug-Resistant Superbugs
Kevin Outterson and CARB-X featured.
August 6, 2020 Boston Globe magazineCARB-X Funds Eligo Bioscience to Develop CRISPR-Based Therapeutics
With a unique approach, Eligo engineers natural predators of bacteria to deliver CRISPR systems that kill antibiotic-resistant superbugs in the gut microbiome.
CARB-X Funds University of Queensland to Accelerate Development of New Class of Last-Resort Antibiotics to Treat Deadly Superbug Infections
First Australian project in the CARB-X portfolio.
CARB-X Expands Awards to Amicrobe
Amicrobe launches new development program for infection prevention in low- and middle-income countries (LMIC), and advances its surgery and trauma antimicrobial project.
CARB-X Funds Module Innovations
Rapid easy-to-use diagnostic would indicate which antibiotics would be effective against the bacterial pathogen causing the UTI.
Carb-X Funds Microbion
Company will develop inhaled drug to treat cystic fibrosis-related lung infections.
May 28, 2020 CARB-X.org